ClinicalTrials.gg
RecruitingNCT07615725Updated Oct 29, 2026

Dry Needling in Multiple Sclerosis

An interventional study of Dry Needling and Sham Dry Needling in Multiple Sclerosis, sponsored by University of South Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by University of South Florida · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 29, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 258 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Planned enrollment
620th of 879
24 · median 50
Started
2026
with 43 others
No phase
381 of 1,192
69 open now
Primary completion
2027-05
later than 113 of 255 live
Registered
1,166th of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 620th largest by planned enrollment of the 879 interventional ones that give a count, is one of 44 that started in 2026, is one of 381 with no phase, reaches primary completion later than 113 of the 255 other live ones, and was the 1,166th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

178 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted at the Human Functional Performance Laboratory in the School of Physical Therapy and Rehabilitation Sciences (MDT Building) at the University of South Florida. The study is supported by the Consortium of Multiple Sclerosis Centers.

The investigators are conducting this study to determine whether a treatment called dry needling can improve chronic pain in the lower body (from the low back to the foot) in people with Multiple Sclerosis. Dry needling involves inserting tiny needles, similar to those used in acupuncture, into specific muscles, such as the thigh or calf muscles. Unlike traditional acupuncture, dry needling targets specific muscle areas to reduce muscle stiffness and pain. Dry needling may help reduce pain without medication. The investigators also aim to determine whether dry needling can improve balance and walking abilities, potentially leading to better day-to-day functioning.

Participants will be assigned to one of two groups. Both groups will receive six treatment sessions. One group will receive actual dry needling, while the other group will receive a sham procedure designed to mimic dry needling. Treatment assignment will be determined randomly, similar to flipping a coin. Neither participants nor the study doctor will choose the assigned treatment. Each participant will have an equal chance of receiving actual dry needling or the sham procedure. Participants will not be informed of the assigned treatment; however, the study doctor will know the treatment assignment.

Participants are being invited to take part in this study because of a diagnosis of Multiple Sclerosis and the presence of chronic pain in the lower body, including the buttocks, thighs, calves, or feet. The investigators aim to determine whether dry needling can help reduce chronic lower-body pain in people with Multiple Sclerosis.

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • Pain
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

**Inclusion Criteria:**

  • Diagnosis of Multiple Sclerosis (MS) based on the McDonald criteria
  • Patient Determined Disease Steps (PDDS) score of 1-5 (ambulatory participants)
  • Ability to communicate in written and spoken English
  • Age 18-80 years
  • Chronic lower-extremity pain lasting more than three consecutive months, with a pain intensity of at least 3 out of 10 on the Numeric Pain Rating Scale (NPRS)

**Exclusion Criteria:**

  • Any neurological comorbidity (e.g., stroke or Parkinson's disease)
  • MS relapse within the past 30 days
  • Current participation in or planned initiation of any pain management intervention (interventional or rehabilitative) targeting the lower extremity
  • Anticipated changes in pain medication during the study period
  • Pregnancy, as determined by a urine pregnancy test
  • Active cancer or chemotherapy within the past year
  • (MoCA) score below 17
  • Known or suspected infection in the lower extremity
  • Deep vein thrombosis
  • Thrombophlebitis
  • Active osteomyelitis in the lower extremity
  • Varicose veins
  • Uncontrolled seizures or epilepsy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Intervention

    Procedure: Dry Needling

  • Sham comparator
    Control

    Procedure: Sham Dry Needling

Interventions

  • ProcedureDry Needling

    Participants will receive dry needling treatment targeting lower-extremity muscles associated with chronic pain in people with multiple sclerosis. The intervention will be delivered over six treatment sessions by a licensed physical therapist trained in dry needling techniques.

  • ProcedureSham Dry Needling

    Participants assigned to the sham dry needling group will receive a control procedure designed to mimic the experience of dry needling without therapeutic needle insertion into the target muscle tissue. The procedure will be delivered over six sessions by a licensed physical therapist trained in dry needling and sham procedures.

06

What researchers measure

Primary outcomes

  1. Percentage of Planned Dry Needling Treatment Sessions Completed

    Treatment adherence will be calculated as the number of completed treatment sessions divided by the total number of planned sessions, multiplied by 100. Each participant is scheduled to receive six treatment sessions. Adherence will range from 0% to 100%, with higher percentages indicating better adherence. The feasibility target is completion of at least 80% of planned sessions.

    Time frame: immediately after the intervention

  2. Percentage of Dry Needling Sites With an Elicited Local Twitch Response

    Practicality will be measured as the percentage of treated muscle sites at which a local twitch response (LTR) is elicited during actual dry needling. An LTR is a brief, involuntary muscle contraction that may occur when a needle stimulates a sensitive area within a muscle. The percentage will be calculated as the number of needling sites with an observed LTR divided by the total number of needling sites assessed, multiplied by 100. Values range from 0% to 100%, with higher percentages indicating more frequent elicitation of an LTR.

    Time frame: immediately after the intervention

  3. Treatment Credibility Score on the Credibility/Expectancy Questionnaire

    Treatment credibility will be assessed using the credibility subscale of the Credibility/Expectancy Questionnaire (CEQ), which measures how logical and believable participants consider the treatment. The subscale consists of three items scored from 1 to 9, producing a total score ranging from 3 to 27. Higher scores indicate greater treatment credibility and a more favorable outcome.

    Time frame: immediately after the intervention

  4. Number of Serious Adverse Events During Study Participation

    Safety will be assessed by recording the number of serious adverse events occurring during study participation. Serious adverse events include events resulting in death, life-threatening conditions, hospitalization, persistent or significant disability, or other medically important conditions. The total number of serious adverse events will be reported for each treatment group. Fewer serious adverse events indicate a more favorable safety outcome. The feasibility hypothesis is that no serious adverse events will occur.

    Time frame: immediately after the intervention

Secondary outcomes

  1. The Patient-Reported Outcomes Measurement Information System Pain Intensity

    Change in Pain Intensity Measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity Short Form 3a (Raw Score: 3-15; Higher Scores Indicate Worse Outcomes)

    Time frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion

  2. Change in Pressure Pain Threshold Measured Using a Pressure Algometer

    Pressure pain threshold (PPT) will be assessed using a pressure algometer to measure mechanical pain sensitivity. Pressure will be gradually applied to selected muscle sites until participants first report that the pressure becomes painful. Higher PPT values indicate lower pain sensitivity and better outcomes. Changes from baseline will be compared between the actual and sham dry needling groups.

    Time frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.

  3. Change in Walking Performance Measured by the Timed 25-Foot Walk Test

    Walking performance will be assessed using the Timed 25-Foot Walk (T25FW) test. Participants will be instructed to walk a distance of 25 feet as quickly and safely as possible. The time required to complete the test will be recorded in seconds. Lower completion times indicate faster walking speed and better mobility. Changes from baseline will be compared between the actual and sham dry needling groups.

    Time frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.

  4. Change in Functional Mobility Measured by the Timed Up and Go Test

    Functional mobility will be assessed using the Timed Up and Go (TUG) test. Participants will stand up from a chair, walk 3 meters, turn around, walk back to the chair, and sit down. The total time required to complete the test will be recorded in seconds. Lower completion times indicate better functional mobility. Changes from baseline will be compared between the actual and sham dry needling groups.

    Time frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.

  5. Change in Postural Sway Measured by an Accelerometer During Static Standing

    Static standing balance will be assessed using a body-worn accelerometer to measure postural sway during quiet standing. Postural sway refers to the movement of the body while maintaining a standing position. Greater sway magnitude indicates poorer balance, while lower values indicate better postural stability. Changes from baseline will be compared between the actual and sham dry needling groups.

    Time frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 11 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
May 29, 2026
StartActual
May 8, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
20 criteria added, 2 removed
What changed in the criteria
  • RemovedInclusion Criteria: Diagnosis of Multiple Sclerosis based on McDonald's Criteria; Patient Determined Disease Steps (PDDS) score of 1-5 (ambulatory participants), the ability to communicate written and spoken English, , age 18-80 and experiencing pain in the lower extremity for more than three consecutive months (3-months) with intensity of 3 or more out of 10 based on numeric pain scale (clinically meaningful pain).
  • RemovedExclusion Criteria: any neurological comorbidity (such as stroke and PD), presence of MS relapse in the last 30 days, current participation in or planned initiation of any pain management intervention (interventional or rehabilitative) targeting the lower extremity, or anticipated changes in pain medication during the study period. Additional exclusion criteria include pregnancy (by urine pregnancy test), any active cancer or chemotherapy within one year, the score of lower than 17 on the MoCA (Montreal Cognitive Assessment), a known or suspected infection in the lower extremity, deep vein thrombosis, thrombophlebitis, active osteomyelitis in the lower extremity, varicose veins and uncontrolled seizures/ epilepsy.
  • Added**Inclusion Criteria:**
  • AddedDiagnosis of Multiple Sclerosis (MS) based on the McDonald criteria
  • AddedPatient Determined Disease Steps (PDDS) score of 1-5 (ambulatory participants)
  • AddedAbility to communicate in written and spoken English
  • AddedAge 18-80 years
  • AddedChronic lower-extremity pain lasting more than three consecutive months, with a pain intensity of at least 3 out of 10 on the Numeric Pain Rating Scale (NPRS)
  • Added**Exclusion Criteria:**
  • AddedAny neurological comorbidity (e.g., stroke or Parkinson's disease)
  • AddedMS relapse within the past 30 days
  • AddedCurrent participation in or planned initiation of any pain management intervention (interventional or rehabilitative) targeting the lower extremity
  • AddedAnticipated changes in pain medication during the study period
  • AddedPregnancy, as determined by a urine pregnancy test
  • AddedActive cancer or chemotherapy within the past year
  • AddedMontreal Cognitive Assessment (MoCA) score below 17
  • AddedKnown or suspected infection in the lower extremity
  • AddedDeep vein thrombosis
  • AddedThrombophlebitis
  • AddedActive osteomyelitis in the lower extremity
  • AddedVaricose veins
  • AddedUncontrolled seizures or epilepsy
Oct 29, 2026
Primary outcomes
4 added, 1 removed
What changed in the outcomes
  • AddedPercentage of Planned Dry Needling Treatment Sessions CompletedTime frame: immediately after the intervention
  • AddedPercentage of Dry Needling Sites With an Elicited Local Twitch ResponseTime frame: immediately after the intervention
  • AddedTreatment Credibility Score on the Credibility/Expectancy QuestionnaireTime frame: immediately after the intervention
  • AddedNumber of Serious Adverse Events During Study ParticipationTime frame: immediately after the intervention
  • RemovedPain PROMISTime frame: Baseline, after completion of dry needling sessions, and 2-month follow-up; changes will be compared with baseline.
Oct 29, 2026
Secondary outcomes
5 added
What changed in the outcomes
  • AddedThe Patient-Reported Outcomes Measurement Information System Pain IntensityTime frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion
  • AddedChange in Pressure Pain Threshold Measured Using a Pressure AlgometerTime frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.
  • AddedChange in Walking Performance Measured by the Timed 25-Foot Walk TestTime frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.
  • AddedChange in Functional Mobility Measured by the Timed Up and Go TestTime frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.
  • AddedChange in Postural Sway Measured by an Accelerometer During Static StandingTime frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Eligibility 20 criteria added, 2 removed
    What changed in the criteria
    • RemovedInclusion Criteria: Diagnosis of Multiple Sclerosis based on McDonald's Criteria; Patient Determined Disease Steps (PDDS) score of 1-5 (ambulatory participants), the ability to communicate written and spoken English, , age 18-80 and experiencing pain in the lower extremity for more than three consecutive months (3-months) with intensity of 3 or more out of 10 based on numeric pain scale (clinically meaningful pain).
    • RemovedExclusion Criteria: any neurological comorbidity (such as stroke and PD), presence of MS relapse in the last 30 days, current participation in or planned initiation of any pain management intervention (interventional or rehabilitative) targeting the lower extremity, or anticipated changes in pain medication during the study period. Additional exclusion criteria include pregnancy (by urine pregnancy test), any active cancer or chemotherapy within one year, the score of lower than 17 on the MoCA (Montreal Cognitive Assessment), a known or suspected infection in the lower extremity, deep vein thrombosis, thrombophlebitis, active osteomyelitis in the lower extremity, varicose veins and uncontrolled seizures/ epilepsy.
    • Added**Inclusion Criteria:**
    • AddedDiagnosis of Multiple Sclerosis (MS) based on the McDonald criteria
    • AddedPatient Determined Disease Steps (PDDS) score of 1-5 (ambulatory participants)
    • AddedAbility to communicate in written and spoken English
    • AddedAge 18-80 years
    • AddedChronic lower-extremity pain lasting more than three consecutive months, with a pain intensity of at least 3 out of 10 on the Numeric Pain Rating Scale (NPRS)
    • Added**Exclusion Criteria:**
    • AddedAny neurological comorbidity (e.g., stroke or Parkinson's disease)
    • AddedMS relapse within the past 30 days
    • AddedCurrent participation in or planned initiation of any pain management intervention (interventional or rehabilitative) targeting the lower extremity
    • AddedAnticipated changes in pain medication during the study period
    • AddedPregnancy, as determined by a urine pregnancy test
    • AddedActive cancer or chemotherapy within the past year
    • AddedMontreal Cognitive Assessment (MoCA) score below 17
    • AddedKnown or suspected infection in the lower extremity
    • AddedDeep vein thrombosis
    • AddedThrombophlebitis
    • AddedActive osteomyelitis in the lower extremity
    • AddedVaricose veins
    • AddedUncontrolled seizures or epilepsy
    Primary outcomes 4 added, 1 removed
    What changed in the outcomes
    • AddedPercentage of Planned Dry Needling Treatment Sessions CompletedTime frame: immediately after the intervention
    • AddedPercentage of Dry Needling Sites With an Elicited Local Twitch ResponseTime frame: immediately after the intervention
    • AddedTreatment Credibility Score on the Credibility/Expectancy QuestionnaireTime frame: immediately after the intervention
    • AddedNumber of Serious Adverse Events During Study ParticipationTime frame: immediately after the intervention
    • RemovedPain PROMISTime frame: Baseline, after completion of dry needling sessions, and 2-month follow-up; changes will be compared with baseline.
    Secondary outcomes 5 added
    What changed in the outcomes
    • AddedThe Patient-Reported Outcomes Measurement Information System Pain IntensityTime frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion
    • AddedChange in Pressure Pain Threshold Measured Using a Pressure AlgometerTime frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.
    • AddedChange in Walking Performance Measured by the Timed 25-Foot Walk TestTime frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.
    • AddedChange in Functional Mobility Measured by the Timed Up and Go TestTime frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.
    • AddedChange in Postural Sway Measured by an Accelerometer During Static StandingTime frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07615725
Responsible party
Sponsor
First posted
May 29, 2026
Start date
May 8, 2026
Primary completion
May 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Amir Tabatabaei, PhD
Contact
tabatabaei@usf.edu
8139747193

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion